GPCR
NASDAQStructure Therapeutics Inc.
Price$42.64+1.73 (+4.22%)
01:30 PM04:15 PM
News · 26 weeks40-78%
2025-12-142026-06-07
Mix2390d
- Insider9(39%)
- SEC Filings6(26%)
- Other4(17%)
- Analyst2(9%)
- Earnings1(4%)
- Leadership1(4%)
Latest news
25 items- PRStructure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for ObesityPublication presented concurrently with oral presentation at American Diabetes Association's 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist Publication and presentation detail dose-dependent, clinically meaningful and statistically significant reductions in body weight with continued weight loss beyond 36 weeks, up to 16.2% during the open-label extension Aleniglipron safety profile reflects well-known GI-related GLP-1 class adverse events, with favorable tolerability profile demonstrated by an overall low (10.4%) discontinuation rate Phase 3 program remains on track to initiate in Q3 2026 Additional p
- PRStructure Therapeutics Announces Participation in Upcoming Investor ConferencesSAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in two upcoming healthcare conferences in June: 2026 Jefferies Global Healthcare Conference Format:Fireside chat and 1x1 meetings Date/time:Wednesday, June 3 at 12:15 p.m. ET Location:New York, NY Goldman Sachs 47th Annual Global Healthcare Conference Format:Fireside chat and 1x1 meetings Date/time:Tuesday, June 9 at 10:00 a.m. ET Location:Miami, FL The live and archived webcasts will be accessible from
- SECSEC Form 10-Q filed by Structure Therapeutics Inc.10-Q - Structure Therapeutics Inc. (0001888886) (Filer)
- SECStructure Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Structure Therapeutics Inc. (0001888886) (Filer)
- SECSEC Form 424B5 filed by Structure Therapeutics Inc.424B5 - Structure Therapeutics Inc. (0001888886) (Filer)
- PRStructure Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsReported positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point and potentially comparable efficacy to injectable GLP1-RAs Data from ACCESS OLE expected in Q3 2026; Data from the Body Composition and Type 2 Diabetes/Obesity data expected in Q4 2026 Positive end-of-Phase 2 feedback received from FDA; aleniglipron Phase 3 initiation on track for Q3 2026 Initial data from Phase 1 single ascending dose (SAD) study of oral small molecule amylin receptor agonist ACCG-2671 and initiation of multiple ascending dose (MAD) study expected in Q3 2026; Phase 1 initiation of second oral
- PRStructure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific SessionsSAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced multiple presentations at the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5–8, 2026 in New Orleans, Louisiana. The presentations include an oral presentation on the ACCESS Phase 2b clinical trial of aleniglipron. Details of the presentations are as follows: Title: ACCESS Trial: Dose-Ranging Evaluation of Aleniglipron, an Oral Small Molecule Nonpeptide GLP-1RA, Demonstrates Meaningful Weight Reductio
- ANALYSTCanaccord Genuity initiated coverage on Structure Therapeutics with a new price targetCanaccord Genuity initiated coverage of Structure Therapeutics with a rating of Buy and set a new price target of $101.00
- SECSEC Form DEF 14A filed by Structure Therapeutics Inc.DEF 14A - Structure Therapeutics Inc. (0001888886) (Filer)
- INSIDERCOO & GC Lang Matthew was granted 184,614 units of Ordinary Shares (SEC Form 4)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lang Matthew3 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by Fmr Llc4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- SECStructure Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Structure Therapeutics Inc. (0001888886) (Filer)
- PRStructure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General CounselSAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the appointment of Matthew Lang, J.D. as Chief Operating Officer and General Counsel. Mr. Lang joins Structure Therapeutics with more than fifteen years of executive leadership experience across global biopharmaceutical organizations, with deep expertise spanning legal, corporate strategy, compliance, risk management, and business development. "Matt is a proven leader with a strong track record of guiding organizations through growth a
- ANALYSTWolfe Research initiated coverage on Structure TherapeuticsWolfe Research initiated coverage of Structure Therapeutics with a rating of Peer Perform
- INSIDERSEC Form 4 filed by Hall Ashley4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by Lin Xichen4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by Ma Yingli4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by Coll Crespo Blas4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by Yoon Jun4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by Stevens Raymond C4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- SECStructure Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Structure Therapeutics Inc. (0001888886) (Filer)
- PRStructure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, AleniglipronPlacebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral GLP-1RAs and comparable efficacy to injectable GLP1-RAs Continued weight loss up to 16.2% (40.5 lbs) observed with 120 mg dose in the ACCESS Open Label Extension (OLE) study at 56 weeks, with no evidence of weight loss plateau Updated interim data from ACCESS OLE and Body Composition studies continue to support improved tolerability and low (2.0 – 3.4%) study drug discontinuations due to adverse events with the lower 2.5 mg starting dose End-of-Phase 2 meeting with FDA scheduled in the second
- INSIDERCHIEF TECHNOLOGY OFFICER Ma Yingli covered exercise/tax liability with 11,313 units of Ordinary Shares, decreasing direct ownership by 10% to 107,391 units (SEC Form 4)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Coll Crespo Blas covered exercise/tax liability with 11,826 units of Ordinary Shares, decreasing direct ownership by 5% to 204,981 units (SEC Form 4)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
GPCR FAQ
6 questionsWhere does GPCR stock trade?
Structure Therapeutics Inc. (GPCR) is listed on NASDAQ.What sector and industry is GPCR in?
Structure Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Structure Therapeutics Inc. go public?
Structure Therapeutics Inc. (GPCR) completed its IPO in 2023.What are analysts saying about GPCR?
Structure Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2026-04-27.What companies are similar to GPCR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare GPCR side-by-side with any of them on Quantisnow.How can I track GPCR on Quantisnow?
Quantisnow aggregates Structure Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GPCR to receive live email and push alerts on every new disclosure.